V brazilian consensus guidelines for detection of anti-cell autoantibodies on hep-2 cells
Carregando...
Data
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Federal de Minas Gerais
Descrição
Tipo
Artigo de periódico
Título alternativo
Primeiro orientador
Membros da banca
Resumo
Background: The V Brazilian Consensus for determination of autoantibodies against cellular constituents on HEp-2 cells,
held in Brasilia (DF, Brazil) on August 27, 2016, discussed the harmonization between the Brazilian Consensus on ANA (BCA)
guidelines and the International Consensus on ANA Patterns (ICAP) recommendations (www.anapatterns.org). Initial
guidelines were formulated by the group of Brazilian experts with the purpose of guiding and enabling Brazilian clinical
laboratories to adopt recommendations and to provide a common standard for national and international consensuses.
Mainbody: Twenty Brazilian researchers and experts from universities and clinical laboratories representing the various
geographical regions of the country participated in the meeting. Three main topics were discussed, namely the
harmonization between the BCA guidelines and latest recommendations of the ICAP initiative, the adjustment of the
terminology and report on HEp-2 patterns, and a reassessment of quality assurance parameters. For the three topics, our aim
was to establish specific guidelines. All recommendations were based on consensus among participants. There was concrete
progress in the adjustment of the BCA guidelines to match the ICAP guidelines. To a certain extent, this derives from the
fact that ICAP recommendations were largely based on the algorithm and recommendations of the IV Brazilian ANA
Consensus, as consistently recognized in the ICAP publications and presentations. However, although there is great overlap
between the two Consensuses, there are some point divergences. These specific items were individually and extensively
discussed, and it was acknowledged that in several points ICAP improved recommendations previously issued by the
Brazilian ANA Consensus and these changes were readily implemented. Regarding some specific topics, the BCA panel of
experts felt that the previously issued recommendations remained relevant and possibly will require further discussion with
ICAP. The term anti-cell antibodies was adopted as the recommended designation, recognizing that the assay addresses
antibodies against antigens in the nucleus and in other cell compartments. However, the acronym ANA HEp-2 was
maintained due to historical and regulatory reasons. It was also signalized that the latest trend in ICAP is to adopt the term
Indirect Immunofluorescent Assay on HEp-2 cell substrate (HEp-2 IIFA). In addition, the quality assurance strategies previously
presented were ratified and emphasized.Conclusion: The V BCA edition was successful in establishing an overall harmonization with the ICAP recommendations for interpretation of the HEp-2 IIFA test, pinpointing the perspectives in filling the remaining gaps between both initiatives.
Abstract
Assunto
Autoanticorpos, Células Hep G2, Anticorpos Antinucleares, Técnica Indireta de Fluorescência para Anticorpo, Padrões de Referência
Palavras-chave
ANA, Autoantibodies, HEp-2 cells, Antinuclear antibodies, Indirect immunofluorescence, Standardization
Citação
Departamento
Curso
Endereço externo
https://advancesinrheumatology.biomedcentral.com/articles/10.1186/s42358-019-0069-5